[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100463632":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":32,"locations":42,"responsibleParty":55,"collaborators":57,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":10,"eligibilityCriteria":65,"healthyVolunteers":62,"sex":66,"minAge":67,"maxAge":10,"enrollmentInfo":68,"targetDuration":10,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":10,"overallStatus":44,"whyStopped":10,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Maastricht Radiation Oncology","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"All patients",null,"The is only 1 arm: all breast cancer patients undergoing surgery.",[13],"Other: Not an extra intervention, tissue taken in routine practice will be used.",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Not an extra intervention, tissue taken in routine practice will be used.","No extra intervention: using tumour tissue taken during surgery in standard of care.",[9],[20,24,27,30],{"name":21,"affiliation":22,"role":23},"Marc Vooijs, PhD","Maastricht University","PRINCIPAL_INVESTIGATOR",{"name":25,"affiliation":26,"role":23},"Marjolein Smidt, MD, PhD","Maastricht University Medical Center",{"name":28,"affiliation":29,"role":23},"Loes Kooreman, MD","Maastricht University Hospital (MUMC+)",{"name":31,"affiliation":29,"role":23},"Maaike De Boer, MD, PhD",[33,38],{"name":34,"role":35,"phone":36,"phoneExt":10,"email":37},"Chantal Overhof","CONTACT","+31 88 44 55 683","chantal.overhof@maastro.nl",{"name":39,"role":35,"phone":40,"phoneExt":10,"email":41},"Ann Claessens","+31 88 44 55 600","ann.claessens@maastro.nl",[43],{"facility":26,"status":44,"city":45,"state":10,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":10},"RECRUITING","Maastricht","6202 AZ","Netherlands","NL",{"type":50,"coordinates":51},"Point",[52,53],5.68889,50.84833,{"lat":53,"lon":52},{"type":56,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[58,59],{"name":26,"class":6},{"name":22,"class":6},"100463632","developing-breast-cancer-organoids-100463632",false,"NCT05317221","Developing Breast (Cancer) Organoids","Inclusion Criteria:\n\n* Female,\n* \\>18 years,\n* Family Anamneses\n* Breast cancer (proven by histopathology), Included subtypes; (ER-,PR- HER2-); (ER+, PR+, HER2-); (ER+, PR+ HER2+).\n* Primary surgery (lumpectomy or mastectomy)\n\nExclusion Criteria:\n\n\\- Physically or mentally incapable or incompetent to sign informed consent","FEMALE","18 Years",{"count":69,"type":70},60,"ESTIMATED","OBSERVATIONAL","Currently, only a few validated biomarkers and models exist guiding or predicting treatment response for specific patient groups. Therefore, a patient-tailored clinical model needs to be developed to address tumour heterogeneity and thereby guide treatment selection on an individualized level. Organoids are patient-derived aggregates that grow in 3D and maintain self- renewal pluripotency and lineage-specific differentiation. Therefore, in contrast with conventional cell lines, they are thought to sustain patient heterogeneity and characteristics and are consequently already in use for drug response screening.\n\nThis now offers the opportunity to investigate if the primary patient breast cancer organoid platform reflects disease progression, treatment response and relapse in patients with different clinical breast cancer subtypes.\n\nGoal: To develop a living biobank from prospective patient-derived breast cancer tissue. The questions we will address are:\n\n1. Do patient-derived breast cancer organoids retain the clinical behaviour and characteristics of the primary patient tumour?\n2. Can BC organoids be used to derive prognostic and predictive biomarkers to inform treatment decisions?\n3. Can the investigators utilize BC organoids to discover novel actionable targets and combination treatments for therapeutic intervention for breast cancer patients?\n4. Can BC organoids be used to discover mechanisms of treatment resistance and relapse?",[74],"Breast Cancer","2026-05-07",{"date":77,"type":78},"2026-05-12","ACTUAL",{"date":80,"type":78},"2022-09-01",{"date":82,"type":70},"2028-05-01",{"name":5,"class":6},1]